Literature DB >> 11197059

Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil.

A Miyamoto1, K Umeshita, M Sakon, H Nagano, H Eguchi, S Kishimoto, K Dono, S Nakamori, M Gotoh, M Monden.   

Abstract

We report a case of advanced hepatocellular carcinoma (HCC), successfully treated by a combination therapy of alpha-interferon (IFN-alpha) and tegafur/uracil (UFT). A 44-year-old Japanese man who underwent a partial hepatectomy for HCC developed tumor recurrence in the liver 10 months after surgery. Transcatheter arterial chemoembolization (TAE) was performed twice within 7 months, but was ineffective. Later, multiple metastatic lesions appeared in the liver, lung and spine. Following the third TAE, a combination therapy of IFN-alpha (10 x 10(6) units, i.m., t.i.w.) and UFT (300 mg, p.o.d.) was started. The treatment resulted in a fall in serum PIVKA-II (protein induced by vitamin K antagonism) levels from 906 mAU to normal levels and a complete resolution of all lung nodules within 6 months. At the latest follow up 24 months after the initiation of combination treatment, the patient was working full-time and showed no evidence of tumor relapse. A combination therapy of IFN-alpha and UFT may be promising for the treatment of advanced HCC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11197059     DOI: 10.1046/j.1440-1746.2000.02289.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin.

Authors:  Michael D Thompson; Mohd Jamal Dar; Satdarshan P S Monga
Journal:  J Hepatol       Date:  2010-10-29       Impact factor: 25.083

2.  A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.

Authors:  Masato Nakamura; Hiroaki Nagano; Hiroshi Wada; Takehiro Noda; Hideo Ota; Bazarragchaa Damdinsuren; Shigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Keizo Dono; Morito Monden
Journal:  J Gastroenterol       Date:  2006-12-08       Impact factor: 7.527

Review 3.  A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine.

Authors:  C Rory Goodwin; Vijay Yanamadala; Alejandro Ruiz-Valls; Nancy Abu-Bonsrah; Ganesh Shankar; Eric W Sankey; Christine Boone; Michelle J Clarke; Mark Bilsky; Ilya Laufer; Charles Fisher; John H Shin; Daniel M Sciubba
Journal:  World Neurosurg       Date:  2016-05-13       Impact factor: 2.104

4.  Regulation of p21/CIP1/WAF-1 mediated cell-cycle arrest by RNase L and tristetraprolin, and involvement of AU-rich elements.

Authors:  Latifa Al-Haj; Perry J Blackshear; Khalid S A Khabar
Journal:  Nucleic Acids Res       Date:  2012-06-19       Impact factor: 16.971

5.  Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.

Authors:  T Noda; H Nagano; I Takemasa; S Yoshioka; M Murakami; H Wada; S Kobayashi; S Marubashi; Y Takeda; K Dono; K Umeshita; N Matsuura; K Matsubara; Y Doki; M Mori; M Monden
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

6.  Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.

Authors:  H Ota; H Nagano; M Sakon; H Eguchi; M Kondo; T Yamamoto; M Nakamura; B Damdinsuren; H Wada; S Marubashi; A Miyamoto; K Dono; K Umeshita; S Nakamori; K Wakasa; M Monden
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.